medwireNews

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.

Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.

CheckMate-227 shows that treatment with nivolumab plus ipilimumab significantly improves progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer and a high tumor mutational burden.

Extension results from the ABILITY-1 trial support the long-term benefits of adalimumab for patients with nonradiographic axial spondyloarthritis.

Researchers have found that the long-term retention rate for a first tumor necrosis factor inhibitor is favorable in patients with spondyloarthritis.

Adjuvant pembrolizumab significantly improves recurrence-free survival, compared with placebo, when given to patients with high-risk stage III melanoma for up to 1 year, researchers report in The New England Journal of Medicine.